Sms Pharmaceuticals Limited · NSE:SMSPHARMA
Sms Pharmaceuticals — Q2 & H1 FY25 Earnings Presentation
22 slides from Sms Pharmaceuticals's earnings presentation, Nov 12, 2024
Slide 1: Exchange filing cover letter for investor presentation
Date: 12th November, 2024 To, The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mu
Slide 2: Investor Presentation Q2 & H1FY25
Investor Presentation Q2 & H1FY25 November 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q2FY25 business and financial highlights
Quarterly Performance Review Q2FY25 business and financial highlights Healthy YoY revenue growth of 18% driven by Revenue volume growth in key APIs EBITDA grew 13% YoY with EBITDA margin at 16%, Profitability stable YoY PAT increased by 20% YoY due to lower finance costs Capex investments pr
Slide 5: Q2FY25 financial highlights
Quarterly Performance Review Q2FY25 financial highlights REVENUE (₹ CRORE) EBITDA (₹ CR) P AT ( ₹ C R ) M AR G I N ( % ) EPS (₹) M AR G I N ( % ) 246 10% 2.04 1.95 20% 1.69 197 18% 17% 16% 7% 7% 7% 7% 167 162 164 1.4 1.4 14% 34 17 29 34 31 16 14 28 12 12 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q2FY24 Q3F
Slide 6: H1FY25 financial highlights
Quarterly Performance Review H1FY25 financial highlights REVENUE (₹ CRORE) EBITDA (₹ CR) P AT ( ₹ C R ) M AR G I N ( % ) EPS (₹) 361 M AR G I N ( % ) 8% 3.61 302 7% 18% 18% 31 2.5 65 54 21 H1FY24 H1FY25 H1FY24 H1FY25 H1FY24 H1FY25 H1FY24 H1FY25 • Revenue from operations at ₹361.20 crore (up 20% YoY)
Slide 7: Key operating metrics Q2FY25
Quarterly Performance Review Key operating metrics Q2FY25 REVENUE BY THERAPEUTI C ARE A (%) REVENUE BY GEOGRAPHY- 2% 5% WI SE (%) 1% 8% 8% 5% 1% 13% 12% 11% 10% 12% 6% 11% 10% 6% 87% 88% 89% 90% 88% 6% 11% 12% 12% Others Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 13% Anti-epileptic 16% Anti-erectile dysfunc
Slide 8: Key operating metrics H1FY25
Quarterly Performance Review Key operating metrics H1FY25 REVENUE BY THERAPEUTI C ARE A (%) REVENUE BY GEOGRAPHY- WI SE (%) 5% 6% 2% 3% 14% 12% 6% 8% 12% 6% 86% 88% 12% 15% Others H1FY24 H1FY25 Anti-epileptic Anti-erectile dysfunction Export Domestic 15% 21% Anti-ulcer Anti-migraine REVENUE BY SEGM
Slide 9: On track to achieve FY25 outlook
Quarterly Performance Review On track to achieve FY25 outlook Metrics Outlook Growth drivers Market leadership in ibuprofen in the next 2-3 years ~20% revenue Revenue growth Ramp up of key APIs Cost optimisation through backward integration and process improvements 20% EBITDA Profitability margin La
Slide 10: Company Overview
Company Overview
Slide 11: SMS at a Glance: Building a sustainable global business
SMS at a Glance Building a sustainable global business From a single unit-product facility to becoming a diversified API player with a global presence, we have… Global and domestic leadership in key APIs An integrated business model with accredited facilities Strong presence in regulatory mark
Slide 12: 35+ history of delivering value
SMS at a Glance 35+ history of delivering value 1989 1995 2000 2003 2007 Inception Scaling Up Building our USFDA audit IPO-listing SMS Pharma was Became the world’s portfolio • Successful first SMS Pharma got started with a single largest Acquired a facility to USFDA audit listed on NSE and unit-pro
Slide 13: State-of-the-art, accredited manufacturing facilities
Our Strengths State-of-the-art, accredited manufacturing facilities Hyderabad unit Vizag unit Hyderabad Vizag Manufacturing capacity: 120 KL for niche small-volume Manufacturing capacity: 3,000 KL for niche large- molecules volume molecules Regulatory approvals: USFDA,EUGMP, Regulatory approvals: KF
Slide 14: Strong thrust on R&D
Our Strengths Strong thrust on R&D New product development Added 18 new products Consistent investment in R&D Allocation of 1.5-2% of sales to R&D Strong partnerships JV with Spanish pharma giant Chemo Iberica S.A. Large technical team 60+ scientists Focus on commercialisation 20+ DMFs filed 13
Slide 15: Diversified to mitigate risk and optimise growth
Our Strengths Diversified to mitigate risk and optimise growth GEOG RAPHY THERAPEUTIC ARE AS CUSTOM ERS 9 7 Domestic Export 2 6 25 80% 15 73% 9 56% 14 30% 20 76 17 Largest client Top 10 Clients 87% contribution from regulated markets in FY24 Top five therapies contributed Largest customer contribute
Slide 16: Marquee customer base
Our Strengths Marquee customer base 15
Slide 17: Experienced BoD to deliver on strategy
Our Strengths Experienced BoD to deliver on strategy Sri Ramesh Babu Potluri Sri Vamsi Krishna Potluri Sri Shravan Kudravallii Sri. Sarvepalli Srinivas Chairman & Managing Executive Director Independent Director Director Director Dr. Sri Sunkara Venkata Sri Dr. Suresh Kumar Smt. Shanti Sree Sri Tril
Slide 18: Strategies for growth
Way forward Strategies for growth Achieve global scale in • Aim to achieve a production target of 1,000 MT per month ibuprofen Leveraging diversified • Strong presence in both key high-margin and high-volume products portfolio for growth Backward integration • Vertical integration of select products
Slide 19: Robust growth is expected in revenue and profitability
Outlook Robust growth is expected in revenue and profitability REVENUE (₹ CR) Key Drivers: 709 563 Portfolio approach to drive revenue 520 522 361 Cost optimisation and enhanced operational efficiency FY21 FY22 FY23 FY24 H1FY25 EBI TDA (₹ CR) M ARGI N (%) 23% Improved profitability through backward
Slide 20: Consolidated P&L statement
Financial statements Consolidated P&L statement YoY QoQ YoY Particulars (₹ Cr) Q2FY25 Q2FY24 Growth Q1FY25 Growth H1FY25 H1FY24 Growth (%) (%) (%) Revenue from operations 196.75 166.64 18% 164.45 20% 361.20 301.98 20% COGS 137.68 116.50 18% 106.16 30% 243.85 204.38 19% Gross profit 59.07 50.14 18% 5
Slide 21: Balance Sheet
Financial statements Balance Sheet Particulars (₹ Cr) H1FY25 FY24 H1FY24 FY23 Total Equity 563.78 536.33 513.77 495.10 Non-Current Liabilities 195.55 166.05 156.68 164.17 Long Term Borrowings 150.61 122.09 113.72 121.75 Current Liabilities 375.40 331.71 341.44 254.91 Short Term Borrowings 134.73 158
Slide 22: Thank You
Mr. Thirumalesh Tumma Aditya Dutta SMS Pharmaceuticals ltd EQSPONENT Partners LLP complianceofficer@smspharma.com smspharma.ir@eqsponent.com Thank You
SMS Pharmaceuticals — Q2 & H1 FY25 Earnings Presentation on 6ix